Product Code: 978-1-68038-581-6
Cell Banking Outsourcing Market Growth & Trends
The global cell banking outsourcing market size is expected to reach USD 35.59 billion by 2030, registering a CAGR of 16.34%, according to a new report by Grand View Research, Inc. Introduction of novel technologies for the collection, testing, and storage of cell lines are expected to boost the cell banking market during the forecast period. Automation in cord blood processing and storage are the key technologies that are expected to affect the growth of the market.
CellTrials.org found that global enrolments of new trials in advanced cell therapy were up almost 30% in the first quarter of 2020. Most of the rise can be associated with cell therapy efforts for treating COVID-19, and over half of those trials for COVID-19 employ umbilical cord MSCs. Hence, the pandemic has created a new market for those companies which are engaged in the manufacturing of MSCs products.
According to a report published by Pharma Intelligence UK Limited, 21 oncological drugs are expected to be launched in 2022. Moreover, these drugs will be used for the treatment of different metabolic disorders which would result in the increased entry of novel biosimilar drugs into the market during the forecast period. For instance, in 2022, Center for Drug Evaluation and Research (CDER), approved 15 new drugs and biological products. Cell lines are highly valuable assets for the production and testing of these biopharmaceuticals. Hence, the increasing number of R&D activities for biosimilar and biologic products is expected to increase demand for the good-quality cell lines, thereby, fueling the demand for banking services.
Monoclonal antibody industry is growing at a rapid pace, owing to the advantages associated with it such as treatment for a wide array of diseases including autoimmune diseases, cancer, and inflammatory diseases. The demand for monoclonal antibodies for the treatment of these diseases is expected to increase during the forecast period, due to the benefits offered by them, which exhibit high efficiency, high specificity, and comparatively lesser side effects.
The increasing number of monoclonal antibody-based viable therapies, as well as the introduction of various new modalities related to their clinical development, are expected to drive the growth of the monoclonal antibodies. A clone with the best properties is chosen and stored in a bank, allowing for the production of monoclonal antibodies to be repeated for a decade. Therefore, the increasing growth of monoclonal antibodies is expected to propel the demand for banking throughout the forecast period.
Human embryonic research poses a moral duty such as respecting the value of human life and preventing suffering. The harvesting of embryonic stem cells violates the duty of respect value for human life as it is a consequence of the destruction of human embryos. In addition, granting of intellectual property rights (IPR) to the product or material used in research and commercialization of such services are the major restraints in cell development. Ethical approval should be obtained before the storage of cell lines and tissues in biorepositories as the technology allows patients identification just from DNA; which may lead to the misuse of tissue for an illegal purpose or for proxy identification of diseases to claim insurance.
Cell Banking Outsourcing Market Report Highlights
- Master cell banking accounted for the largest market share in 2022, owing to rise in these facilities across the globe. Moreover, master cell banks are useful for the preparation of working cell banks and thus find applicability in various research and development perspectives for gene therapy thereby resulting to segment growth
able of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
- 1.2. Information Procurement
- 1.3. Information Or Data Analysis
- 1.4. Market Scope & Segment Definition
- 1.5. Market Model
- 1.5.1. Market Study, By Company Market Share
- 1.5.2. Regional Analysis
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Technological Advancement Involving Cell Banking
- 3.2.1.2. Patent Expiration Of Blockbuster Biologics
- 3.2.1.3. Rising Demand For Monoclonal Antibodies
- 3.2.1.4. Growing R&D Investments In Biotechnology Sector
- 3.2.1.5. Increasing Prevalence Of Cancer
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Ethical Concern Related To Stem Cell Research
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
- 4.1. Cell Banking Outsourcing Market: Type Movement Analysis
- 4.2. Master Cell Banking
- 4.2.1. Master Cell Banking Market, 2018 - 2030 (USD Million)
- 4.3. Working Cell Banking
- 4.3.1. Working Cell Banking Market, 2018 - 2030 (USD Million)
- 4.4. Viral Cell Banking
- 4.4.1. Viral Cell Banking Market, 2018 - 2030 (USD Million)
Chapter 5. Cell-Type Business Analysis
- 5.1. Cell Banking Outsourcing Market: Cell-Type Movement Analysis
- 5.2. Stem Cell
- 5.2.1. Stem Cell Market, 2018 - 2030 (USD Million)
- 5.2.2. Cord Cell Banking
- 5.2.2.1. Cord Cell Banking Market, 2018 - 2030 (USD Million)
- 5.2.3. Embryonic Stem Cell Banking
- 5.2.3.1. Embryonic Stem Cell Banking Market, 2018 - 2030 (USD Million)
- 5.2.4. Adult Stem Cell Banking
- 5.2.4.1. Adult Stem Cell Banking Market, 2018 - 2030 (USD Million)
- 5.2.5. Dental Stem Cell Banking
- 5.2.5.1. Dental Stem Cell Banking Market, 2018 - 2030 (USD Million)
- 5.2.6. IPS Stem Cell Banking
- 5.2.6.1. IPS Stem Cell Banking Market, 2018 - 2030 (USD Million)
- 5.3. Non-Stem Cell
- 5.3.1. Non-Stem Cell Market, 2018 - 2030 (USD Million)
Chapter 6. Phase Business Analysis
- 6.1. Cell Banking Outsourcing Market: Phase Movement Analysis
- 6.2. Bank Storage
- 6.2.1. Bank Storage Market, 2018 - 2030 (USD Million)
- 6.2.2. Master Cell Bank Preparation
- 6.2.2.1. Master Cell Bank Preparation Market, 2018 - 2030 (USD Million)
- 6.2.3. Working Cell Bank Preparation
- 6.2.3.1. Working Cell Bank Preparation Market, 2018 - 2030 (USD Million)
- 6.2.4. Cell Storage Stability Testing
- 6.2.4.1. Cell Storage Stability Testing Market, 2018 - 2030 (USD Million)
- 6.3. Bank Characterization & Testing
- 6.3.1. Bank Characterization & Testing Market, 2018 - 2030 (USD Million)
- 6.3.2. Safety Testing
- 6.3.2.1. Safety Testing Market, 2018 - 2030 (USD Million)
- 6.3.2.1.1. Viral Cell Banks
- 6.3.2.1.1.1. Viral Cell Banks Market, 2018 - 2030 (USD Million)
- 6.3.2.1.2. Microbial Cell Banks
- 6.3.2.1.2.1. Microbial Cell Banks Market, 2018 - 2030 (USD Million)
- 6.3.3. Gene Expression Testing
- 6.3.3.1. Gene Expression Testing Market, 2018 - 2030 (USD Million)
- 6.3.4. Karyology Testing
- 6.3.4.1. Karyology Testing Market, 2018 - 2030 (USD Million)
- 6.3.5. Gene Sequencing Testing
- 6.3.5.1. Gene Sequencing Testing Market, 2018 - 2030 (USD Million)
- 6.4. Bank Preparation
- 6.4.1. Bank Preparation Market, 2018 - 2030 (USD Million)
- 6.4.2. Master Cell Bank Preparation
- 6.4.2.1. Master Cell Bank Preparation Market, 2018 - 2030 (USD Million)
- 6.4.3. Working Cell Bank Preparation
- 6.4.3.1. Working Cell Bank Preparation Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Cell Banking Outsourcing Market Share By Region, 2022 & 2030
- 7.2. North America
- 7.2.1. SWOT Analysis
- 7.2.2. North America Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.2.3. U.S.
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. U.S. Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.2.4. Canada
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Competitive Scenario
- 7.2.4.3. Canada Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. SWOT Analysis
- 7.3.2. Europe Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. UK Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.4. Germany
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Germany Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.5. France
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Competitive Scenario
- 7.3.5.3. France Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.6. Italy
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Competitive Scenario
- 7.3.6.3. Italy Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.7. Spain
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Competitive Scenario
- 7.3.7.3. Spain Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.8. Denmark
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Competitive Scenario
- 7.3.8.3. Denmark Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.9. Sweden
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Competitive Scenario
- 7.3.9.3. Sweden Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.3.10. Norway
- 7.3.10.1. Key Country Dynamics
- 7.3.10.2. Competitive Scenario
- 7.3.10.3. Norway Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. SWOT Analysis
- 7.4.2. Asia Pacific Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Japan Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.4. China
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. China Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.5. India
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. India Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Australia Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Thailand Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.4.8. South Korea
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. South Korea Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. SWOT Analysis
- 7.5.2. Latin America Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.5.3. Brazil
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Brazil Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Mexico Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.5.5. Argentina
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Argentina Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.6. MEA
- 7.6.1. SWOT Analysis
- 7.6.2. MEA Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.6.3. South Africa
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. South Africa Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.6.4. Saudi Arabia
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Saudi Arabia Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.6.5. UAE
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. UAE Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
- 7.6.6. Kuwait
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Kuwait Cell Banking Outsourcing Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2022
- 8.4. Company Profiles/Listing
- 8.4.1. Bio Outsource (Sartorious)
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. BSL Bioservice
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Cryo-Cell International, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Charles River Laboratories
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. LifeCell
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. GBI
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Lonza
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. SGS Societe Generale de Surveillance SA
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Perfectus Biomed Limited
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives